Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01065454 · ClinicalTrials.gov registry record · Phase 2

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

A Phase 2 study, sponsored by Bayer.

Completed
Registry status
Phase 2
Development phase
202
Enrollment target

NCT01065454: Completed Phase 2 study, sponsored by Bayer.

NCT01065454 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 202 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01065454, a Phase 2 study, has completed, sponsored by Bayer.

COMPLETED
Registry status
Phase 2
Development phase
202 participants
Enrollment target

Study Summary

The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction

Primary Outcome

Mean pulmonary arterial pressure (PAPmean) is a directly measured hemodynamic parameter. PAPmean is recorded during a right heart catheterization.

Interventions

  • DRUG Placebo
  • DRUG Riociguat (Adempas, BAY63-2521)

Trial Details

FieldValue
Enrollment Target 202 participants
Start Date 2010-04-14
Est. Completion 2025-07-23
Phase Phase 2
Bayer

591 total trials

What the finished NCT01065454 record still lists

NCT01065454 is an interventional study that assigns participants to a tested intervention. The registered 202 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01065454 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01065454 about?

NCT01065454 is a clinical study titled "A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction". The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction

What is the current status of trial NCT01065454?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 2010-04-14. Estimated completion is 2025-07-23.

What interventions are being tested in trial NCT01065454?

The interventions under investigation include: Placebo (DRUG), Riociguat (Adempas, BAY63-2521) (DRUG).

Who is sponsoring clinical trial NCT01065454?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01065454's enrollment target sits among peer trials

202 301st of 2000 higher than 1,699 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05272254 · 202 participants · Phase 2

    Povidone Iodine Efficacy Study

  • NCT05701280 · 202 participants · NA

    Pilot/Pivotal Study of DBS+Rehab After Stroke

  • NCT05932589 · 202 participants

    Neurophysiologic Biomarkers in Rett Syndrome

  • NCT06014931 · 202 participants · NA

    Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01065454, the US trial registry maintained by the National Library of Medicine. NCT01065454 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.